News

Drug developer Proteostasis Therapeutics, Inc., which is currently studying protein homeostasis regulation as a treatment for orphan and neurodegenerative diseases such as cystic fibrosis (CF), recently named Po-Shun Lee, MD as their new vice-president of clinical development. The pulmonary and critical care physician, who has been responsible for leading research programs on…

Virginia-based surgical and medical instrument manufacturer PulmoFlow, Inc. announced Tuesday, December 2 that the US Food and Drug Administration has granted final approval of its New Drug Application for the Kitabis Pak. The drug is a co-packaging of tobramycin inhalation solution and the PARI LC PLUS® Reusable Nebulizer, which is the first…

A new study published in the Orphanet Journal of Rare Diseases, presented the effectiveness of Cysteamine for the treatment of Cystic Fibrosis. The study, entitled  “Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis” was conducted by NovaBiotics Ltd.  researchers. Cystic…

Two recently published reviews in peer-reviewed journals plus another study highlight the potential utility of ceragenins or cationic selective antimicrobials (CSAs) — a proprietary, patented, first-in-class small molecule technology platform for fighting bacterial infections, such as pulmonary infections associated with cystic fibrosis (CF) and hospital acquired infections associated with…

Researchers in the Netherlands found that although adolescents with cystic fibrosis had a higher breathing response to exercise, they were able to breathe adequately enough to be able to perform a moderate exercise task. Cystic fibrosis is one of the most commonly occurring chronic diseases of the lungs…

Corbus Pharmaceuticals has been invited to present during this Thursday’s VirtualInvestorConferences.com on its lead pipeline product Resunab™, indicated for the treatment of serious inflammatory and fibrotic diseases, namely cystic fibrosis and diffuse scleroderma. Representing the company during the upcoming online, live event is CEO Yuval Cohen,…

The Arkansas Chapter of the Cystic Fibrosis Foundation held another successful edition of its Breath of Life Gala last Tuesday, November 25th at the Marriott Hotel in Little Rock. The fundraising event, which has become a tradition in Arkansas, gathered 360 guests and featured a candid speech from Katherine Lambert-Pennington,…

Nottingham University Hospital NHS Trust in the U.K. has announced a new state of the art facility utilizing technology from enterprise partners, including Cisco. The new £6.6 million East Midlands Cystic Fibrosis Adult CF Centre campus at Nottingham University Hospital’s (NUH) NHS Trust City Hospital is designed to…

Bayer HealthCare, a global leader in respiratory medicine, recently announced it has received qualified infectious disease product (QIDP) designation from the US Food and Drug Administration for two pipeline inhalation antibiotic drugs: Amikacin inhale and Ciprofloxacin dry powder. The approval of novel inhaled antibiotics are of particular interest to the…

In the United Kingdom, The Cystic Fibrosis Trust along with the children’s charity Action Medical Research, are funding a laboratory test of an inhaled treatment targeting lung dehydration in Cystic Fibrosis. Cystic fibrosis (CF) is a condition that usually affects children and young people and includes symptoms such…